Marek Ma, MD | |
1820 Dresden Dr Ne, Brookhaven, GA 30319-3632 | |
(215) 301-3948 | |
Not Available |
Full Name | Marek Ma |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Location | 1820 Dresden Dr Ne, Brookhaven, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184660367 | NPI | - | NPPES |
1011505150001 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | MD424073 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Marek Ma, MD 1820 Dresden Dr Ne, Brookhaven, GA 30319-3632 Ph: (215) 301-3948 | Marek Ma, MD 1820 Dresden Dr Ne, Brookhaven, GA 30319-3632 Ph: (215) 301-3948 |
News Archive
The American Dental Association (ADA) looks forward to working with Congress in continuing to reduce oral health disease in Indian country, said Dr. Jerry Long, chairman of the ADA's Council on Government Affairs.
The U.S. Army Accessions Command (USAAC) and the Healthy Weight Commitment Foundation (HWCF) today announced a partnership aimed at countering the trend toward obesity among young people that could among other downsides diminish the pool of qualified young Americans available for military duty.
Multiple-birth infants had a significantly higher risk of wrong-patient order errors compared with singletons in neonatal intensive care units, according to a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian Hospital.
Biocompatible nanocapsules, loaded with an amino acid and equipped with an enzyme now combine two anti-tumor strategies into a synergistic treatment concept. Researchers hope this increases effectiveness and decreases side effects.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
› Verified 9 days ago